{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:37:42Z","timestamp":1778535462288,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00270-024-03726-9","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T18:01:36Z","timestamp":1715709696000},"page":"1210-1221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcome of Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma: Glass Versus Resin Microsphere"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6768-4396","authenticated-orcid":false,"given":"Gyoung Min","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-3439","authenticated-orcid":false,"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8237-5628","authenticated-orcid":false,"given":"Jong Yun","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4334-3797","authenticated-orcid":false,"given":"Sungmo","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-8050","authenticated-orcid":false,"given":"Seung Up","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5363-2496","authenticated-orcid":false,"given":"Beom Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"11","key":"3726_CR1","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00270-022-03072-8","volume":"45","author":"B Guiu","year":"2022","unstructured":"Guiu B, Garin E, Allimant C, Edeline J, Salem R. TARE in hepatocellular carcinoma: from the right to the left of BCLC. Cardiovasc Intervent Radiol. 2022;45(11):1599\u2013607.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"19","key":"3726_CR2","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients With hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913\u201321.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3726_CR3","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624\u201336.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3726_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 4","key":"3726_CR5","first-page":"163","volume":"43","author":"R Salem","year":"2020","unstructured":"Salem R, Johnson GE, Riaz A, Bishay VL, Kim E, Padia S. Yttrium-90 glass microspheres in the treatment of hepatocellular carcinoma: the LEGACY study. Cardiovasc Intervent Radiol. 2020;43(Suppl 4):163.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"3726_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"8","key":"3726_CR7","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1097\/01.RVI.0000233785.75257.9A","volume":"17","author":"R Salem","year":"2006","unstructured":"Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251\u201378.","journal-title":"J Vasc Interv Radiol"},{"issue":"9 Pt 2","key":"3726_CR8","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1016\/S1051-0443(07)61790-4","volume":"13","author":"R Salem","year":"2002","unstructured":"Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13(9 Pt 2):S223-229.","journal-title":"J Vasc Interv Radiol"},{"issue":"7","key":"3726_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12149-011-0499-6","volume":"25","author":"YH Kao","year":"2011","unstructured":"Kao YH, Tan EH, Ng CE, Goh SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med. 2011;25(7):455\u201361.","journal-title":"Ann Nucl Med"},{"issue":"10","key":"3726_CR10","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M, Garin E, Maccauro M, et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49(10):3340\u201352.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"3726_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2967\/jnumed.122.264996","volume":"64","author":"M Watanabe","year":"2023","unstructured":"Watanabe M, Grafe H, Theysohn J, et al. Voxel-based dosimetry predicts hepatotoxicity in hepatocellular carcinoma patients undergoing radioembolization with (90)Y glass microspheres. J Nucl Med. 2023;64(7):1102\u20138.","journal-title":"J Nucl Med"},{"issue":"8","key":"3726_CR12","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.2967\/jnumed.116.184713","volume":"58","author":"A Van Der Gucht","year":"2017","unstructured":"Van Der Gucht A, Jreige M, Denys A, et al. Resin versus glass microspheres for (90)Y transarterial radioembolization: comparing survival in unresectable hepatocellular carcinoma using pretreatment partition model dosimetry. J Nucl Med. 2017;58(8):1334\u201340.","journal-title":"J Nucl Med"},{"issue":"7","key":"3726_CR13","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00270-017-1594-4","volume":"40","author":"JR Kallini","year":"2017","unstructured":"Kallini JR, Gabr A, Thorlund K, et al. Comparison of the adverse event profile of TheraSphere((R)) with SIR-Spheres((R)) for the treatment of unresectable hepatocellular carcinoma: a systematic review. Cardiovasc Intervent Radiol. 2017;40(7):1033\u201343.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"3726_CR14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jvir.2016.01.147","volume":"27","author":"DM Biederman","year":"2016","unstructured":"Biederman DM, Titano JJ, Tabori NE, et al. Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: resin versus glass microspheres. J Vasc Interv Radiol. 2016;27(6):812\u201321.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"3726_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u201380.","journal-title":"Hepatology"},{"issue":"2","key":"3726_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68(2):723\u201350.","journal-title":"Hepatology"},{"issue":"12","key":"3726_CR17","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3348\/kjr.2022.0822","volume":"23","author":"A Korean Liver Cancer","year":"2022","unstructured":"Korean Liver Cancer A, National Cancer Center K. KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol. 2022;23(12):1126\u2013240.","journal-title":"Korean J Radiol"},{"issue":"3","key":"3726_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00270-017-1826-7","volume":"41","author":"JH Kwon","year":"2018","unstructured":"Kwon JH, Kim GM, Han K, et al. Safety and efficacy of transarterial radioembolization combined with chemoembolization for bilobar hepatocellular carcinoma: a single-center retrospective study. Cardiovasc Intervent Radiol. 2018;41(3):459\u201365.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"3726_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"8","key":"3726_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00270-017-1703-4","volume":"40","author":"DK Filippiadis","year":"2017","unstructured":"Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40(8):1141\u20136.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"3726_CR21","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jvir.2021.03.535","volume":"32","author":"S Frantz","year":"2021","unstructured":"Frantz S, Matsuoka L, Vaheesan K, et al. Multicenter evaluation of survival and toxicities of hepatocellular carcinoma following radioembolization: analysis of the RESiN registry. J Vasc Interv Radiol. 2021;32(6):845\u201352.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"3726_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00270-020-02642-y","volume":"44","author":"T Helmberger","year":"2021","unstructured":"Helmberger T, Golfieri R, Pech M, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21\u201335.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"3726_CR23","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/hep.24451","volume":"54","author":"B Sangro","year":"2011","unstructured":"Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868\u201378.","journal-title":"Hepatology"},{"issue":"3","key":"3726_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00270-019-02404-5","volume":"43","author":"L Cardarelli-Leite","year":"2020","unstructured":"Cardarelli-Leite L, Chung J, Klass D, et al. Ablative transarterial radioembolization improves survival in patients with HCC and portal vein tumor thrombus. Cardiovasc Intervent Radiol. 2020;43(3):411\u201322.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"3726_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jhep.2013.05.025","volume":"59","author":"R Golfieri","year":"2013","unstructured":"Golfieri R, Bilbao JI, Carpanese L, et al. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol. 2013;59(4):753\u201361.","journal-title":"J Hepatol"},{"issue":"4","key":"3726_CR26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00259-019-04588-x","volume":"47","author":"AS Pasciak","year":"2020","unstructured":"Pasciak AS, Abiola G, Liddell RP, et al. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. Eur J Nucl Med Mol Imaging. 2020;47(4):816\u201327.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"3726_CR27","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342\u201352.","journal-title":"Hepatology"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03726-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-024-03726-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03726-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T15:03:39Z","timestamp":1725635019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-024-03726-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3726"],"URL":"https:\/\/doi.org\/10.1007\/s00270-024-03726-9","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"24 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}